YASUSHI HORIMASU

Last Updated :2023/02/02

Affiliations, Positions
Hiroshima University Hospital, Assistant Professor
Self-introduction
In addition to medical care and research in the field of respiratory medicine in general, I'm also focusing on student education.

Basic Information

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Respiratory organ internal medicine

Educational Activity

Course in Charge

  1. 2022, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2022, Undergraduate Education, Intensive, Symptomatology, Diagnosis and Treatment
  3. 2022, Undergraduate Education, Intensive, Introduction to clinical clerkship
  4. 2022, Undergraduate Education, Intensive, Practice of Medicine I
  5. 2022, Undergraduate Education, Intensive, Practice of Medicine II
  6. 2022, Undergraduate Education, First Semester, Internalz Medicine II

Research Activities

Academic Papers

  1. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer, BMC PULMONARY MEDICINE, 22(1), 20220630
  2. Vocal cord dysfunction detected by a three-dimensional image of dynamic change in respiratory resistance in a patient with difficult-to-treat asthma: a case report, JOURNAL OF ASTHMA, 59(6), 1157-1161, 20220603
  3. Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with the High Expression of IgG4, INTERNAL MEDICINE, 61(7), 1043-1048, 2022
  4. Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive-stage small cell lung cancer: Two case reports, THORACIC CANCER, 12(21), 2956-2960, 202111
  5. Pulmonary Alveolar Proteinosis with Severe Respiratory Failure Improved by Segmental Lung Lavage with Fiberoptic Bronchoscopy under General Anesthesia, INTERNAL MEDICINE, 61(3), 389-393, 2022
  6. Pneumatosis Intestinalis following Radiation Esophagitis during Chemoradiotherapy for Lung Cancer: A Case Report, CASE REPORTS IN ONCOLOGY, 14(3), 1454-1459, 2021
  7. Accelerated decline in lung function in adults with a history of remitted childhood asthma, EUROPEAN RESPIRATORY JOURNAL, 59(1), 20220101
  8. First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations, THORACIC CANCER, 13(5), 771-774, 202203
  9. Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPD gene polymorphisms, BMC MEDICAL GENETICS, 15, 20140108
  10. Solitary Fibrous Tumor with Rapid Progression after 16 Years' Follow Up, INTERNAL MEDICINE, 53(6), 617-621, 2014
  11. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis, RESPIRATORY MEDICINE, 108(7), 1031-1039, 201407
  12. MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis, RESPIROLOGY, 20(3), 439-444, 201504
  13. MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model, CANCER SCIENCE, 106(7), 921-928, 201507
  14. Histological Quantification of Gene Silencing by Intratracheal Administration of Dry Powdered Small-Interfering RNA/Chitosan Complexes in the Murine Lung, PHARMACEUTICAL RESEARCH, 32(12), 3877-3885, 201512
  15. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis, ORPHANET JOURNAL OF RARE DISEASES, 11, 20160423
  16. Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis, DISEASE MARKERS, 2016
  17. Long-term pulmonary complications of chemical weapons exposure in former poison gas factory workers, INHALATION TOXICOLOGY, 28(8), 343-348, 201607
  18. AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis, RESPIROLOGY, 22(5), 965-971, 201707
  19. Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets, BMC Med Genet, 18(88)
  20. MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study, BMC Cancer, 17(1), 263
  21. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis, Respir Med, 123, 105
  22. Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets, BMC MEDICAL GENETICS, 18, 20170818
  23. CLINICAL AND MOLECULAR FEATURES OF RAPIDLY PROGRESSIVE CHRONIC HYPERSENSITIVITY PNEUMONITIS, SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 34(1), 48-57, 2017
  24. Chronic Intestinal Pseudo-obstruction and Orthostatic Hypotension Associated with Small Cell Lung Cancer that Improved with Tumor Reduction after Chemoradiotherapy, INTERNAL MEDICINE, 56(19), 2627-2631, 2017
  25. AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, ONCOTARGET, 8(55), 94382-94392, 20171107
  26. Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis, INTERNAL MEDICINE, 56(24), 3327-3331, 2017
  27. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 81(1), 131-139, 201801
  28. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis, RESPIRATORY MEDICINE, 123, 105-109, 201702
  29. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma, LUNG CANCER, 119, 21-24, 201805
  30. Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma, EUROPEAN RESPIRATORY JOURNAL, 51(5), 20180501
  31. Effectiveness of Tolvaptan in a Case of Refractory Syndrome of Inappropriate Secretion of Antidiuretic Hormone Caused by Small Cell Lung Cancer, 58(2), 132-137, 20180820
  32. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32(5), 1155-1160, 2018
  33. Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice, MOLECULAR THERAPY-NUCLEIC ACIDS, 12, 698-706, 20180907
  34. Plasminogen activator inhibitor-1 serves an important role in radiation-induced pulmonary fibrosis, EXPERIMENTAL AND THERAPEUTIC MEDICINE, 16(4), 3070-3076, 201810
  35. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study, MOLECULAR AND CLINICAL ONCOLOGY, 9(5), 539-544, 201811
  36. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody A retrospective cohort study, MEDICINE, 97(49), 201812
  37. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, CANCER LETTERS, 442, 31-39, 2019
  38. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98(5), 201902
  39. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98(12), 201903
  40. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 23(4), 2984-2994, 201904
  41. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress, FREE RADICAL BIOLOGY AND MEDICINE, 136, 52-59, 20190520
  42. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152, 44-50, 201906
  43. C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis, Respiration, 98(3), 212-220
  44. A Case of Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis, Internal Medicine, 58, 3129-3132
  45. Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, RESPIRATORY MEDICINE, 172, 202010
  46. Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosis, RESPIRATORY INVESTIGATION, 58(6), 465-472, 202011
  47. Coexisting TIF1 gamma-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1 gamma Antibody-positive Dermatomyositis, INTERNAL MEDICINE, 59(20), 2553-2558, 2020
  48. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers, JAMA NETWORK OPEN, 3(11), 20201112
  49. Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer, CANCER SCIENCE, 112(1), 369-379, 202101
  50. Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma, CLINICAL RESPIRATORY JOURNAL, 15(1), 48-55, 202101
  51. Two Cases of Cranial Nerve Metastasis Treated with Radiotherapy and Chemotherapy in Patients with Lung Adenocarcinoma, CASE REPORTS IN ONCOLOGY, 13(3), 1495-1500, 2020
  52. Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma, INTERNAL MEDICINE, 60(4), 611-615, 2021
  53. Concomitant emphysema might increase the false-negative rate of urinary antigen tests in patients with pneumococcal pneumonia: results from a retrospective study, EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 40(4), 871-877, 202104
  54. Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer, ANTICANCER RESEARCH, 41(3), 1497-1506, 202103
  55. Pulmonary lymphangitic carcinomatosis from recurrent gastric cancer 19 years after primary resection: a case report, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14(2), 484-488, 202104
  56. Pulmonary arteriovenous malformation exhibiting recanalization >10 years after coil embolization Two case reports, MEDICINE, 99(2), 202001
  57. Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone, ANTICANCER RESEARCH, 41(5), 2661-2667, 202105
  58. Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients, SCIENTIFIC REPORTS, 11(1), 20210512
  59. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study, PULMONARY PHARMACOLOGY & THERAPEUTICS, 67, 202104
  60. D-dimer can be a diagnostic marker for cisplatin-related aortic thrombosis A case report, MEDICINE, 100(7), 20210219
  61. A machine-learning based approach to quantify fine crackles in the diagnosis of interstitial pneumonia A proof-of-concept study, MEDICINE, 100(7), 20210219
  62. IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis, PLOS ONE, 16(6), 20210604
  63. Gemcitabine maintenance therapy after gemcitabine and platinum drug chemotherapy for naive stage IIIB/IV squamous cell lung cancer: a phase II study, ANTI-CANCER DRUGS, 32(7), 767-772, 202108
  64. Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity, STEM CELL RESEARCH & THERAPY, 12(1), 20210823
  65. Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis, STEM CELL RESEARCH & THERAPY, 12(1), 20210916
  66. Analysis of microRNA Expression in Liquid-Based Cytology Samples May Be Useful for Primary Lung Cancer Diagnosis, AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 156(4), 644-652, 202110
  67. Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 88(5), 857-865, 202111
  68. Potential benefits of volumetric modulated arc therapy to reduce the incidence of >= grade 2 radiation pneumonitis in radiotherapy for locally advanced non-small cell lung cancer patients, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 51(12), 1729-1735, 202112

Publications such as books

  1. 2018, Drug-Induced Lung Injury, Blood Tests for the Diagnosis and/or Management of DLI: What Are the Clinical Significances of KL-6, SP-A, SP-D, and DLST in DLI?, Springer, 2018, Scholarly Book, Joint work, Horimasu Y, Hattori N, 978-981-10-4466-3

Invited Lecture, Oral Presentation, Poster Presentation

  1. Comparative analysis of multiple gene polymorphisms for acute exacerbation of idiopathic pulmonary fibrosis, Ohshimo S, Yamaoka C, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Hirohashi N, Tanigawa K, Bonella F, Guzman J, Costabel U, Kohno N., European Respiratory Society International Congress 2015, 2016/09/26, Without Invitation, English
  2. FAM13A Polymorphism as a Prognostic Factor in Patients with Idiopathic Pulmonary Fibrosis, Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Bonella F*, Guzman J*, Costabel U*, Kohno N, American Thoracic Society International Conference 2016, 2016/05/13, Without Invitation, English
  3. FAM13A Polymorphism as a Prognostic Factor in Idiopathic Pulmonary Fibrosis: 1st Study in the Japanese Population, Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Bonella F, Guzman J, Costabel U, ,Kohno N, 2016/04/08, Without Invitation, English
  4. Long-term pulmonary complications of sulfur mustard exposure in former poison gas factory workers, Nishimura Y, Iwamoto H, Ishikawa N, Hattori N, Horimasu Y, Ohshimo S, Fujitaka K, Kondo K, Hamada H, Awai K, Kohno N, the 1st Asia Oceania Workshop of Pulmonary Functional Imaging (1st AOWPFI) and 8th meeting of the Japanese Society of Pulmonary Functional Imaging (8th JSPFI), 2016/01/29, Without Invitation, English
  5. MUC1 gene polymorphism and serum KL-6 in lung adenocarcinoma, Horimasu Y, Ishikawa N, Tanaka S, Iwamoto H, Ohshimo S, Fujitaka K, Hattori N, Hamada H, Kohno N., European Respiratory Society International Congress 2015, 2015/09/26, Without Invitation, English
  6. Growth differentiation factor-15 (GDF-15) as prognostic factor in German patients with idiopathic pulmonary fibrosis, Ohshimo S, Hamai K, Bonella F, Yamaoka C, Horimasu Y, Iwamoto H, Ishikawa N, Fujitaka K, Murai H, Hamada H, Hattori N, Hirohashi N, Tanigawa K, Guzman J, Costabel U, Kohno N., American Thoracic Society International Conference 2015, 2015/05/17, Without Invitation, English
  7. Serum KL-6 level is an independent prognostic factor for the patients with lung adenocarcinoma, Yasushi Horimasu, Noboru Hattori, Takeshi Masuda, Taku Nakashima, Hiroshi Iwamoto, Kazunori Fujitaka, Hiroshi Murai, Morihito Okada, Hironobu Hamada, Nobuoki Kohno, 2015/04/19, Without Invitation, Japanese
  8. HRCT Findings as a Predictive Factor for Acute Exacerbation of Idiopathic Pulmonary Fibrosis, Chihiro Yamaoka, Yasushi Horimasu, Hiroshi Iwamoto, Shinichiro Ohshimo, Kazunori Fujitaka, Hiroshi Murai, Noboru Hattori, Hironobu Hamada, Nobuoki Kohno, 2015/04/17, Without Invitation, English
  9. Annual changes in pulmonary function are independent prognostic factors for the patients with chronic hypersensitivity pneumonia, Yasushi Horimasu, Nobuhisa Ishikawa, Taku Nakashima, Hiroshi Iwamoto, Tadashi Senoo, Shinichiro Ohshimo, Kazunori Fujitaka, Yoshinori Haruta, Hiroshi Murai, Noboru Hattori, Nobuoki Kohno, ERS Annual Congress Munich 2014, 2014/09/07, Without Invitation, English, European Respiratory Society, Munich
  10. Annual decline in lung function can predict the prognosis of patients with chronic hypersensitivity pneumonia, Yasushi Horimasu, Nobuhisa Ishikawa, Taku Nakashima, Hiroshi Iwamoto, Tadashi Senoo, Shinichiro Ohshimo, Kazunori Fujitaka, Yoshinori Haruta, Hiroshi Murai, Noboru Hattori, Nobuoki Kohno, ATS 2014 - American Thoracic Society International Conference, 2014/05/18, Without Invitation, English, American Thoracic Society, San Diego
  11. Bronchoalveolar lavage cellular pattern can predict the prognosis of patients with chronic hypersensitivity pneumonia, Yasushi Horimasu, Nobuhisa Ishikawa, Taku Nakashima, Tadashi Seno, Shinichiro Ohshimo, Kazunori Fujitaka, Yoshinori Haruta, Hiroshi Murai, Noboru Hattori, Nobuoki Kohno, 2014/04/27, Without Invitation, English